Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER_GOV × Sarcoma × durvalumab × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

OTHER 4 OTHER_GOV 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neoplasm Metastasis 2 Stomach Neoplasms 1 Sarcoma 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma, Follicular 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

High-Throughput Nucleotide Sequencing 2 Base Sequence 2 trametinib 1 spartalizumab 1 palbociclib 1 olaparib 1 nilotinib 1 glasdegib 1 futibatinib 1 durvalumab 1 dabrafenib 1 ceritinib 1 capmatinib 1 camrelizumab 1 Radiotherapy 1 Nivolumab 1 Lapatinib 1 Irinotecan 1 Ipilimumab 1 Environment 1 Doxorubicin 1 Docetaxel 1 Cryosurgery 1 Albumin-Bound Paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03784014 2025-12-11

MULTISARC

Institut National de la Santé Et de la Recherche Médicale, France

Phase 3 Active not recruiting

Neoplasm Metastasis, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡